Cargando…
Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City
Omicron is the most mutated SARS-CoV-2 variant—a factor that can affect transmissibility, disease severity, and immune evasiveness. Its genomic surveillance is important in cities with millions of inhabitants and an economic center, such as Mexico City. Results. From 16 November to 31 December 2021,...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950183/ https://www.ncbi.nlm.nih.gov/pubmed/35336952 http://dx.doi.org/10.3390/v14030545 |
_version_ | 1784675079760642048 |
---|---|
author | Cedro-Tanda, Alberto Gómez-Romero, Laura de Anda-Jauregui, Guillermo Garnica-López, Dora Alfaro-Mora, Yair Sánchez-Xochipa, Sonia García-García, Eulices F. Mendoza-Vargas, Alfredo Frías-Jiménez, Emmanuel J. Moreno, Bernardo Campos-Romero, Abraham Moreno-Camacho, José L. Alcantar-Fernández, Jonathan Ortíz-Ramírez, Jesús Benitez-González, Mariana Trejo-González, Roxana Aguirre-Chavarría, Daniel Núñez-Martínez, Marcela E. Uribe-Figueroa, Laura Angulo, Ofelia Ruiz, Rosaura Hidalgo-Miranda, Alfredo Herrera, Luis A. |
author_facet | Cedro-Tanda, Alberto Gómez-Romero, Laura de Anda-Jauregui, Guillermo Garnica-López, Dora Alfaro-Mora, Yair Sánchez-Xochipa, Sonia García-García, Eulices F. Mendoza-Vargas, Alfredo Frías-Jiménez, Emmanuel J. Moreno, Bernardo Campos-Romero, Abraham Moreno-Camacho, José L. Alcantar-Fernández, Jonathan Ortíz-Ramírez, Jesús Benitez-González, Mariana Trejo-González, Roxana Aguirre-Chavarría, Daniel Núñez-Martínez, Marcela E. Uribe-Figueroa, Laura Angulo, Ofelia Ruiz, Rosaura Hidalgo-Miranda, Alfredo Herrera, Luis A. |
author_sort | Cedro-Tanda, Alberto |
collection | PubMed |
description | Omicron is the most mutated SARS-CoV-2 variant—a factor that can affect transmissibility, disease severity, and immune evasiveness. Its genomic surveillance is important in cities with millions of inhabitants and an economic center, such as Mexico City. Results. From 16 November to 31 December 2021, we observed an increase of 88% in Omicron prevalence in Mexico City. We explored the R346K substitution, prevalent in 42% of Omicron variants, known to be associated with immune escape by monoclonal antibodies. In a phylogenetic analysis, we found several independent exchanges between Mexico and the world, and there was an event followed by local transmission that gave rise to most of the Omicron diversity in Mexico City. A haplotype analysis revealed that there was no association between haplotype and vaccination status. Among the 66% of patients who have been vaccinated, no reported comorbidities were associated with Omicron; the presence of odynophagia and the absence of dysgeusia were significant predictor symptoms for Omicron, and the RT-qPCR Ct values were lower for Omicron. Conclusions. Genomic surveillance is key to detecting the emergence and spread of SARS-CoV-2 variants in a timely manner, even weeks before the onset of an infection wave, and can inform public health decisions and detect the spread of any mutation that may affect therapeutic efficacy. |
format | Online Article Text |
id | pubmed-8950183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89501832022-03-26 Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City Cedro-Tanda, Alberto Gómez-Romero, Laura de Anda-Jauregui, Guillermo Garnica-López, Dora Alfaro-Mora, Yair Sánchez-Xochipa, Sonia García-García, Eulices F. Mendoza-Vargas, Alfredo Frías-Jiménez, Emmanuel J. Moreno, Bernardo Campos-Romero, Abraham Moreno-Camacho, José L. Alcantar-Fernández, Jonathan Ortíz-Ramírez, Jesús Benitez-González, Mariana Trejo-González, Roxana Aguirre-Chavarría, Daniel Núñez-Martínez, Marcela E. Uribe-Figueroa, Laura Angulo, Ofelia Ruiz, Rosaura Hidalgo-Miranda, Alfredo Herrera, Luis A. Viruses Article Omicron is the most mutated SARS-CoV-2 variant—a factor that can affect transmissibility, disease severity, and immune evasiveness. Its genomic surveillance is important in cities with millions of inhabitants and an economic center, such as Mexico City. Results. From 16 November to 31 December 2021, we observed an increase of 88% in Omicron prevalence in Mexico City. We explored the R346K substitution, prevalent in 42% of Omicron variants, known to be associated with immune escape by monoclonal antibodies. In a phylogenetic analysis, we found several independent exchanges between Mexico and the world, and there was an event followed by local transmission that gave rise to most of the Omicron diversity in Mexico City. A haplotype analysis revealed that there was no association between haplotype and vaccination status. Among the 66% of patients who have been vaccinated, no reported comorbidities were associated with Omicron; the presence of odynophagia and the absence of dysgeusia were significant predictor symptoms for Omicron, and the RT-qPCR Ct values were lower for Omicron. Conclusions. Genomic surveillance is key to detecting the emergence and spread of SARS-CoV-2 variants in a timely manner, even weeks before the onset of an infection wave, and can inform public health decisions and detect the spread of any mutation that may affect therapeutic efficacy. MDPI 2022-03-06 /pmc/articles/PMC8950183/ /pubmed/35336952 http://dx.doi.org/10.3390/v14030545 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cedro-Tanda, Alberto Gómez-Romero, Laura de Anda-Jauregui, Guillermo Garnica-López, Dora Alfaro-Mora, Yair Sánchez-Xochipa, Sonia García-García, Eulices F. Mendoza-Vargas, Alfredo Frías-Jiménez, Emmanuel J. Moreno, Bernardo Campos-Romero, Abraham Moreno-Camacho, José L. Alcantar-Fernández, Jonathan Ortíz-Ramírez, Jesús Benitez-González, Mariana Trejo-González, Roxana Aguirre-Chavarría, Daniel Núñez-Martínez, Marcela E. Uribe-Figueroa, Laura Angulo, Ofelia Ruiz, Rosaura Hidalgo-Miranda, Alfredo Herrera, Luis A. Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City |
title | Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City |
title_full | Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City |
title_fullStr | Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City |
title_full_unstemmed | Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City |
title_short | Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City |
title_sort | early genomic, epidemiological, and clinical description of the sars-cov-2 omicron variant in mexico city |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950183/ https://www.ncbi.nlm.nih.gov/pubmed/35336952 http://dx.doi.org/10.3390/v14030545 |
work_keys_str_mv | AT cedrotandaalberto earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT gomezromerolaura earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT deandajaureguiguillermo earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT garnicalopezdora earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT alfaromorayair earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT sanchezxochipasonia earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT garciagarciaeulicesf earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT mendozavargasalfredo earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT friasjimenezemmanuelj earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT morenobernardo earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT camposromeroabraham earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT morenocamachojosel earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT alcantarfernandezjonathan earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT ortizramirezjesus earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT benitezgonzalezmariana earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT trejogonzalezroxana earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT aguirrechavarriadaniel earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT nunezmartinezmarcelae earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT uribefigueroalaura earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT anguloofelia earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT ruizrosaura earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT hidalgomirandaalfredo earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity AT herreraluisa earlygenomicepidemiologicalandclinicaldescriptionofthesarscov2omicronvariantinmexicocity |